Literature DB >> 15288238

Drug interactions in oncology.

Jos H Beijnen1, Jan H M Schellens.   

Abstract

Drug interactions are an ongoing concern in treatment of cancer, especially when cytotoxic drugs are being used. However, the clinical relevance of these interactions is not always investigated. Drug interactions can be pharmaceutical, pharmacokinetic, or pharmacodynamic. They can also be wanted (eg, use of ciclosporin to enhance the oral bioavailability of paclitaxel); unwanted (eg, combination of the antiviral agent sorivudine and oral fluorouracil analogues can lead to fatal complications); between cytotoxic drugs, cytotoxic drugs and non-cytotoxic drugs; or with pharmaceutical vehicles. Potential interactions between anticancer drugs and over-the-counter or alternative medicines and herbs should not be underestimated. More attention should be given to the recognition of potential drug interactions in the preclinical and early clinical development phase of a new anticancer drug. Here, we provide a comprehensive overview of drug interactions, with selected examples.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288238     DOI: 10.1016/S1470-2045(04)01528-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  61 in total

1.  Phenytoin toxicity in a patient receiving 5-fluorouracil-based chemotherapy for metastatic colorectal cancer.

Authors:  Sara M Kuruvilla; Som D Mukherjee
Journal:  Curr Oncol       Date:  2011-12       Impact factor: 3.677

Review 2.  Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.

Authors:  Bertrand Rochat
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Potential drug interactions in patients with a history of cancer.

Authors:  L Chen; W Y Cheung
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

4.  Evaluation of drug interactions in patients treated with antidepressants at a tertiary care cancer center.

Authors:  Lincy Subha Lal; Amy Zhuang; Frank Hung; Chun Feng; Rebecca Arbuckle; Michael J Fisch
Journal:  Support Care Cancer       Date:  2011-04-26       Impact factor: 3.603

5.  Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Authors:  Lot A Devriese; Petronella Els O Witteveen; Jantien Wanders; Kenneth Law; Geoff Edwards; Larisa Reyderman; William Copalu; Fuping Peng; Serena Marchetti; Jos H Beijnen; Alwin D R Huitema; Emile E Voest; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

6.  Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.

Authors:  Dirk Theile; Zoltan Gal; Rolf Warta; Juan Pablo Rigalli; Bernd Lahrmann; Niels Grabe; Christel Herold-Mende; Gerhard Dyckhoff; Johanna Weiss
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

7.  Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.

Authors:  Kehua Wu; Larry House; Jacqueline Ramírez; Michael J Seminerio; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2013-09-20       Impact factor: 12.531

8.  Modifiable risk factors for intracerebral hemorrhage: study of anticoagulated patients.

Authors:  Elana C Fric-Shamji; Mohammed F Shamji; James Cole; Brien G Benoit
Journal:  Can Fam Physician       Date:  2008-08       Impact factor: 3.275

9.  Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.

Authors:  David I Quinn; John Nemunaitis; Jyotsna Fuloria; Carolyn D Britten; Nashat Gabrail; Lorrin Yee; Milin Acharya; Kai Chan; Nadine Cohen; Assen Dudov
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

10.  Characteristics of potential drug-related problems among oncology patients.

Authors:  Arjan Bulsink; Alex L T Imholz; Jacobus R B J Brouwers; Frank G A Jansman
Journal:  Int J Clin Pharm       Date:  2013-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.